Sio Gene Therapies Inc.
SIOX · NASDAQ
3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.05 | 0.01 | 0.02 |
| FCF Yield | -124.44% | -34.50% | -111.87% | -82.82% |
| EV / EBITDA | 0.17 | -0.63 | 0.00 | -0.82 |
| Quality | ||||
| ROIC | -115.37% | -27.35% | -87.52% | -126.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 1.44 | 0.93 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -29.91% | 30.62% | 49.61% | 30.94% |
| Safety | ||||
| Net Debt / EBITDA | 0.86 | 4.01 | 0.00 | 0.52 |
| Interest Coverage | -2,676.56 | -42.93 | -15.49 | -16.87 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |